Court is due to hear argument between Israel-based pharmaceutical company and teams that want to introduce their own versions of top-selling Copaxone multiple sclerosis drug.
The U.S. Supreme Court on Wednesday is set to wade into Teva Pharmaceutical Industries Ltd's fight over patent protections for Copaxone, its top-selling multiple sclerosis drug, in one of the most important business cases of the justices' new term.